Sanofi
- Country
- 🇫🇷France
- Ownership
- Public
- Employees
- 87.9K
- Market Cap
- $141.3B
- Website
- http://www.sanofi.com
- Introduction
Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Vaccines. The Pharmaceuticals segment comprises the commercial operations of the following global franchises: specialty care, diabetes and cardiovascular, established prescription products and generics, and research, development, and production activities. The Consumer Healthcare segment includes the commercial operations for its Consumer Healthcare products. The Vaccines segment consists commercial operations of Sanofi Pasteur. The company was founded in 1973 and is headquartered in Paris, France.
Nolpitantium Besylate In Patients With Ulcerative Colitis a Double-Blind, Placebo Controlled Efficacy and Safety Study
- Conditions
- First Posted Date
- 2005-10-04
- Last Posted Date
- 2008-12-10
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 307
- Registration Number
- NCT00232258
- Locations
- 🇸🇪
Sanofi-Aventis Administrative Office, Bromma, Sweden
Double Blind Placebo COntrolled Dose Ranging studY of the eFficacy and safEty of SSR149744c 300 or 600 mg for the Conversion of Atrial Fibrillation / fluttEr
- Conditions
- First Posted Date
- 2005-10-04
- Last Posted Date
- 2012-05-08
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 150
- Registration Number
- NCT00232310
- Locations
- 🇵🇹
Sanofi-Aventis Administrative Office, Porto Salvo, Portugal
Double Blind Placebo Controlled Dose Ranging Study of the Efficacy and Safety of SSR149744c 100 or 300 mg for the Prevention of ventrICular ARrhythmia-triggered Icd interventiOnS
- Conditions
- First Posted Date
- 2005-10-04
- Last Posted Date
- 2012-05-08
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 153
- Registration Number
- NCT00232297
- Locations
- 🇨🇭
Sanofi-Aventis Administrative Office, Geneva, Switzerland
Rasburicase Versus Allopurinol in Tumor Patients at Risk for Hyperuricemia and Tumor Lysis Syndrome
- Conditions
- Interventions
- First Posted Date
- 2005-09-30
- Last Posted Date
- 2010-01-12
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 280
- Registration Number
- NCT00230178
- Locations
- 🇺🇸
University of Florida Health Science Center at Jacksonville, Jacksonville, Florida, United States
🇺🇸New York Methodist Hospital, Brooklyn, New York, United States
🇺🇸Rocky Mountain Cancer Center, Denver, Colorado, United States
Study of Rasburicase as Treatment or Prevention of Hyperuricemia Associated With Tumor Lysis Syndrome in Patients With Relapsed or Refractory Lymphoma, Leukemia, or Solid Tumor Malignancy
- Conditions
- First Posted Date
- 2005-09-30
- Last Posted Date
- 2009-03-30
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 94
- Registration Number
- NCT00230217
- Locations
- 🇺🇸
Alta Bates Comprehensive Cancer Center, Berkley, California, United States
🇺🇸University of Florida Health Science Center at Jacksonville, Jacksonville, Florida, United States
🇺🇸University of Pennsylvania Health Systems, Philadelphia, Pennsylvania, United States
Long Term Safety and Efficacy of Teriflunomide (HMR1726) in Multiple Sclerosis With Relapses
- First Posted Date
- 2005-09-28
- Last Posted Date
- 2015-03-25
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 147
- Registration Number
- NCT00228163
- Locations
- 🇨🇦
Investigational Site Number 12, Montreal, Canada
🇨🇦Investigational Site Number 11, Montreal, Canada
🇨🇦Investigational Site Number 17, Vancouver, Canada
Study of the Effect of SR57667B on the Progression of Symptoms in Patients With Parkinson's Disease
- Conditions
- First Posted Date
- 2005-09-28
- Last Posted Date
- 2008-12-23
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 564
- Registration Number
- NCT00228150
- Locations
- 🇬🇧
Sanofi-Aventis Administrative Office, Guilford Surrey, United Kingdom
Atherosclerosis Underlying Development Assessed by Intima-Media Thickness in Patients on Rimonabant
- Conditions
- Interventions
- First Posted Date
- 2005-09-28
- Last Posted Date
- 2016-05-20
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 661
- Registration Number
- NCT00228176
- Locations
- 🇬🇧
Sanofi-Aventis Administrative Office, Guildford Surrey, United Kingdom
Study of the Effect of SR57667B on 18F-Dopa PET Imaging in Patients With Parkinson's Disease
- Conditions
- First Posted Date
- 2005-09-22
- Last Posted Date
- 2008-12-23
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 183
- Registration Number
- NCT00220272
- Locations
- 🇬🇧
Sanofi-Aventis Administrative Office, Guildford Surrey, United Kingdom
Safety, Tolerability, and Immunogenicity of a Clostridium Difficile Toxoid Vaccine in Healthy Elderly Volunteers
- First Posted Date
- 2005-09-22
- Last Posted Date
- 2012-04-11
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 48
- Registration Number
- NCT00214461
- Locations
- 🇺🇸
Orlando Clinical Research Center, Orlando, Florida, United States
🇺🇸University of Kentucky, Lexington, Kentucky, United States